Metabolic Disease:

Testing

‘Individuals with T2DM, obesity or overweight, atherosclerosis, dyslipidemia, and high inflammatory biomarkers should be considered as atherosclerotic cardiovascular disease (ASCVD) patients. ASCVD risk is indicated by concomitant elevation of hs-CRP and Lp-PLA2 levels, which in combination correlate with a very high risk of CVD even in individuals with low or moderately elevated LDL-C levels. Taken together, all these findings suggest that Lp-PLA2 could be considered as a new vascular specific biomarker to predict CVD risk in patients with metabolic diseases.’

De Stefano, Alessandro, Liliana Mannucci, Federica Tamburi, Carmine Cardillo, Francesca Schinzari, Valentina Rovella, Steven Nisticò, Luigi Bennardo, Nicola Di Daniele, and Manfredi Tesauro. “Lp-PLA 2 , a New Biomarker of Vascular Disorders in Metabolic Diseases.” International Journal of Immunopathology and Pharmacology 33 (January 2019): 205873841982715. https://doi.org/10.1177/2058738419827154 .

De Stefano, Alessandro, Liliana Mannucci, Federica Tamburi, Carmine Cardillo, Francesca Schinzari, Valentina Rovella, Steven Nisticò, Luigi Bennardo, Nicola Di Daniele, and Manfredi Tesauro. “Lp-PLA 2 , a New Biomarker of Vascular Disorders in Metabolic Diseases.” International Journal of Immunopathology and Pharmacology 33 (January 2019): 205873841982715. https://doi.org/10.1177/2058738419827154.